
CureVision is a MedTech startup based in Munich, Germany, revolutionizing chronic wound care with its all-in-one solution. Their technology enables contactless, precise, and rapid wound analysis and documentation, reducing assessment time by up to 90%. The system features AI-supported wound detection, automated measurement of length, width, and depth, as well as tissue and temperature analysis. This digitalized wound management is optimized for hospitals, clinics, nursing homes, and home care, streamlining the process from patient selection to a digital wound report. The company's commitment to innovation is underscored by its MDR approval and multiple awards, including the German Startup and Digitalization Prize and the Health-i Award.

CureVision is a MedTech startup based in Munich, Germany, revolutionizing chronic wound care with its all-in-one solution. Their technology enables contactless, precise, and rapid wound analysis and documentation, reducing assessment time by up to 90%. The system features AI-supported wound detection, automated measurement of length, width, and depth, as well as tissue and temperature analysis. This digitalized wound management is optimized for hospitals, clinics, nursing homes, and home care, streamlining the process from patient selection to a digital wound report. The company's commitment to innovation is underscored by its MDR approval and multiple awards, including the German Startup and Digitalization Prize and the Health-i Award.
Product: MDR-approved AI-powered handheld system + web platform for contactless 3D wound measurement, tissue analysis and digital wound reports
Founded: 2021
Location: Munich and Potsdam, Germany
Employees: 15
Performance claim: Automated wound report in ~2 minutes; up to 90% faster than manual methods
Funding (reported): Total external funding reported: 2,890,000 USD (last funding date 2024-03-28)
Chronic wound assessment, measurement, documentation and management in clinical and care environments.
2021
MedTech
“Reported supporters and investors include Angels4Health, EIT Health, Luminate, AQAL Group, the European Union, and (per funding profiles) BioLab Holdings”